€4.7M seed investment SAFE/Convertible

We are developing the first drug-induced in vivo stem cell therapy for the safe and durable treatment of chronic inflammatory diseases (CID). Our therapeutic concept combines the benefits of autologous and allogeneic stem cell therapies, BUT without the significant economic downsides of cell manipulations / production- because the stem cell effect is induced inside the body ("in vivo"), by simple injection of our HO2RT prodrugs. Our HO2RT prodrugs are Small Molecule Drug Conjugates (SMDCs) that achieve sustained drug release and target a tightly self-regulated cellular pathway. Proof of therapeutic Concept was achieved notably in severe UC and periodontitis rodent models. Periodontitis is our initial indication for human proof of concept and is a low-hanging fruit to quickly and easily access to the crowded CID market- it is a grossly neglected disease. Yet, only €42.5M at most is needed for complete drug development from IND-enabling stage to market. To eliminate any potential bias stemming from partial spontaneous gum regrowth in rodents, we will test two very distinct HO2RT prodrugs in a pilot, non-GLP dog efficacy study. The veterinary HO2RT prodrug (HO2RT-201) will be out-licensed and the resulting royalty income estimated to bring $11M-50M/Year starting in 2031 will fund the entire clinical development of HO2RT-101 for human periodontitis, plus other R&D collaborative projects to advance other assets**.** We will seek to partner HO2RT-101 -ideally, once approved- to exploit the distribution and sales channels of a large company (e.g. MedTech) while contemplating life-cycle management as a drug-device combination product. Thus, to reach Ph2 clinical entry by 2030, we need €8.5M (€4.7M + €3.8M). Initial investors will hardly face downstream dilution since we likely will not need additional rounds of investment past 2031.